Insmed's Phase III for inhaled amikacin placed on hold
This article was originally published in Scrip
Executive Summary
The US FDA has placed a clinical hold on Insmed's Phase III trials for lead candidate Arikace (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease.